Inventor · disambiguated record
Tracy Zimmermann
Also filed as: ZIMMERMANN TRACY · ZIMMERMANN TRACY S · ZIMMERMANN TRACY STAGE
22 granted patents·8 pending applications·441 citations·filing 2005–2025
96Inventor score
Files withALNYLAM PHARMACEUTICALS INC18ARROWHEAD PHARMACEUTICALS INC3ARROWHEAD RES CORP2HINKLE GREGORY2VORNLOCHER HANS-PETER2
Top patents by PatentIndex Score
30 records- 0199US9796974B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Oct 24, 2017·119 cites·30 claims
- 0298US11406716B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·8 cites·21 claims
- 0398US10668170B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 2, 2020·22 cites·22 claims
- 0498US9399775B2RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jul 26, 2016·51 cites·36 claims
- 0597US11286486B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Mar 29, 2022·8 cites·28 claims
- 0697US9290760B2Modified iRNA agentsRAJEEV KALLANTHOTTATHIL G·Filed 2011·Granted Mar 22, 2016·100 cites·33 claims
- 0796US8334373B2Nuclease resistant double-stranded ribonucleic acidVORNLOCHER HANS-PETER·Filed 2011·Granted Dec 18, 2012·30 cites·22 claims
- 0896US7928217B2Nuclease resistant double-stranded ribonucleic acidALNYLAM PHARMACEUTICALS INC·Filed 2005·Granted Apr 19, 2011·37 cites·19 claims
- 0995US10683501B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 16, 2020·8 cites·28 claims
- 1095US10208307B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Feb 19, 2019·16 cites·75 claims
- 1194US10570391B2RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Feb 25, 2020·12 cites·45 claims
- 1292US12049628B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Jul 30, 2024·1 cites·44 claims
- 1388US2024279652A1RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1488US2025075211A1TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1586US10287582B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted May 14, 2019·3 cites·18 claims
- 1685US9540643B2Organic compositions to treat HSF1-related diseasesARROWHEAD RES CORP·Filed 2015·Granted Jan 10, 2017·3 cites·21 claims
- 1785US8481509B2Organic compositions to treat HSF1-related diseasesHINKLE GREGORY·Filed 2012·Granted Jul 9, 2013·6 cites·20 claims
- 1884US12290573B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted May 6, 2025·0 cites·20 claims
- 1984US8293718B2Organic compositions to treat HSF1-related diseasesHINKLE GREGORY·Filed 2010·Granted Oct 23, 2012·5 cites·51 claims
- 2083US12091661B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Sep 17, 2024·0 cites·20 claims
- 2183US9096637B2Organic compositions to treat HSF1-related diseasesARROWHEAD RES CORP·Filed 2013·Granted Aug 4, 2015·3 cites·22 claims
- 2283US8993746B2Nuclease resistant double-stranded ribonucleic acidVORNLOCHER HANS-PETER·Filed 2012·Granted Mar 31, 2015·3 cites·10 claims
- 2382US8623838B2Organic compositions to treat HSF1-related diseasesCHEN JINYUN·Filed 2012·Granted Jan 7, 2014·6 cites·22 claims
- 2482US2025213720A1MODIFIED RNAi AGENTSALNYLAM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2577US11091761B2Organic compositions to treat HSF1-related diseasesARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Aug 17, 2021·0 cites·20 claims
- 2677US2023010288A1Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2770US2020318111A1Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2868US2018008724A1MODIFIED RNAi AGENTSALNYLAM PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2964US2010222417A1Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissuesALNYLAM PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 3059US2023114649A1HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tracy Zimmermann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →